Evidence map›Paper›PMID 34739862›Full record

ReviewThe Lancet. Global health2022

Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines.

Miquel Oliu-Barton, Bary S R Pradelski, Yann Algan, Michael G Baker, Agnes Binagwaho, Gregory J Dore, Ayman El-Mohandes, Arnaud Fontanet, Andreas Peichl, Viola Priesemann and 3 more

Abstract readReview
In one paragraph

Review in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. NMR-Metabolomics in COVID-19 Research.Advances in experimental medicine and biology · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. The global failure of facing the pandemic.Global health action · 2022
    Article
  15. Article
  16. Article
  17. Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Miquel Oliu-BartonUniversité Paris-Dauphine-PSL, Paris, France; Bruegel, Brussels, Belgium; Esade Centre for Economic Policy, Madrid, Spain. Electronic address: miquel.oliu.barton@normalesup.org.
Bary S R PradelskiFrench National Centre for Scientific Research, Grenoble, France; Oxford-Man Institute of Quantitative Finance, University of Oxford, Oxford, UK.
Yann AlganHEC Paris, Jouy-en-Josas, France; Council of Economic Analysis, Paris, France.
Michael G BakerUniversity of Otago, Wellington, New Zealand.
Agnes BinagwahoUniversity of Global Health Equity, Kigali, Rwanda.
Gregory J DoreKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Ayman El-MohandesCity University of New York, New York, NY, USA.
Arnaud FontanetEmerging Diseases Epidemiology Unit, Institut Pasteur, Université de Paris, Paris, France; Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France.
Andreas PeichlUniversity of Munich, Munich, Germany; ifo Institute, Munich, Germany; CESifo, Munich, Germany.
Viola PriesemannMax Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.
Guntram B WolffBruegel, Brussels, Belgium.
Gavin YameyCentre for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, USA.
Jeffrey V LazarusBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is increasing evidence that elimination strategies have resulted in better outcomes for public health, the economy, and civil liberties than have mitigation strategies throughout the first year of the COVID-19 pandemic. With vaccines that offer high protection against severe forms of COVID-19, and increasing vaccination coverage, policy makers have had to reassess the trade-offs between different options. The desirability and feasibility of eliminating SARS-CoV-2 compared with other strategies should also be re-evaluated from the perspective of different fields, including epidemiology, public health, and economics. To end the pandemic as soon as possible-be it through elimination or reaching an acceptable endemic level-several key topics have emerged centring around coordination, both locally and internationally, and vaccine distribution. Without coordination it is difficult if not impossible to sustain elimination, which is particularly relevant in highly connected regions, such as Europe. Regarding vaccination, concerns remain with respect to equitable distribution, and the risk of the emergence of new variants of concern. Looking forward, it is crucial to overcome the dichotomy between elimination and mitigation, and to jointly define a long-term objective that can accommodate different political and societal realities.

Indexed as

COVID-19 VaccinesCOVID-19Disease EradicationHumansPandemicsSARS-CoV-2VaccinationCOVID-19 Vaccines

Identifiers

PMID34739862
PMCPMC8563003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.